Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), has shown promising outcomes in the survival of patients with non-squamous NSCLC when given alone or in combination with platinum-based chemotherapy [151,152]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.